Exact Sciences Business Model Canvas
Investor-ready Business Model Canvas for a leading molecular diagnostics innovator
Unlock the full strategic blueprint behind Exact Sciences's Business Model Canvas. This in-depth map shows how the company creates value through innovative diagnostics, commercial partnerships, and diversified revenue streams while spotlighting competitive advantages and key risks. Purchase the complete, editable canvas for section-by-section insights ideal for investor decks, strategic planning, or benchmarking.
Partnerships
Payer and insurer alliances
Reimbursement agreements with Medicare (coverage since 2014) and payers covering over 90% of commercial lives ensure broad access to Cologuard and precision oncology tests. These partnerships lower patient out-of-pocket costs and accelerate adoption. Joint value dossiers and outcomes data drive favorable policies, while multiyear payer contracts improve revenue visibility.
Healthcare provider networks
Primary care (about 70% of screening referrals), GI specialists and oncology clinics serve as critical referral sources for Exact Sciences tests. Co-developed clinical pathways with health systems and networks embed tests into standard care across hundreds of organizations. Targeted clinician education and streamlined sample logistics reduce ordering friction and speed result delivery. Key opinion leaders accelerate evidence adoption and drive guideline inclusion.
Laboratory and logistics partners
Exact Sciences leverages CLIA-certified labs and high-throughput partners to scale testing quality within the ~100 billion USD US clinical lab market in 2024, while cold-chain and courier networks ensure reliable sample transport. Integrated LIMS and interoperability trim turnaround times, and capacity partners enable spikes in demand and new-test launches.
Research institutions and biopharma
Research centers supply cohorts, biobanks and trial sites to validate biomarkers, enabling Exact Sciences to link diagnostics to targeted therapies with biopharma partners; in 2024 Exact Sciences reported roughly $3.3B revenue, supporting expanded RWE programs that strengthened clinical utility claims and yielded co-publications boosting credibility.
- Academic cohorts and biobanks
- Biopharma companion diagnostics
- RWE studies (2024 scale-up)
- Co-publications increase adoption
Regulatory and advocacy collaborations
Engagement with FDA, CMS, and guideline bodies aligns test development and reimbursement, leveraging Medicare coverage of Cologuard for beneficiaries 50–85 every 3 years. Patient advocacy groups such as American Cancer Society amplify awareness and adherence. Public health and policy partnerships drive population screening and support USPSTF screening guidance for ages 45–75.
- Medicare coverage: beneficiaries 50–85 every 3 years
- USPSTF: screening 45–75
- Advocacy: ACS partnership
Medicare coverage, payer reach >90%, primary care referrals ~70%, 2024 revenue $3.3B
Reimbursement deals (Medicare coverage since 2014; payers cover >90% commercial lives) and multiyear contracts drive access and revenue visibility. Referral partnerships (primary care ~70% of screening referrals) and health systems embed Cologuard into care. CLIA labs, couriers and biopharma RWE alliances scaled capacity—2024 revenue ~$3.3B.
| Metric | 2024 |
|---|---|
| Revenue | $3.3B |
| US lab market | $100B |
| Commercial lives covered | >90% |
| Primary care referrals | ~70% |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas tailored to Exact Sciences that maps its nine core blocks—value propositions, customer segments, channels, revenue streams, key resources, activities, partners, cost structure, and customer relationships—against real-world diagnostics and molecular screening operations. Includes competitive advantages, SWOT-linked insights, and polished narratives ideal for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Exact Sciences that condenses its diagnostic and screening strategy into a one-page snapshot, saving hours of structuring while enabling quick comparisons, team collaboration, and fast deliverables for boardrooms or analysts.
Activities
Assay R&D and biomarker discovery
Continuous innovation across multi-target stool DNA (Cologuard), blood-based, and tissue assays drives Exact Sciences pipeline expansion; Cologuard showed 92% sensitivity and 87% specificity for colorectal cancer in pivotal validation.
Rigorous analytical validation programs confirm sensitivity and specificity benchmarks for each assay.
Advanced bioinformatics refines molecular signatures from large clinical datasets, while a growing IP portfolio secures competitive advantage.
Clinical trials and evidence generation
Prospective DeeP-C trial showed Cologuard sensitivity for colorectal cancer 92.3% and specificity 89.8%. Retrospective and real-world studies corroborate clinical validity and utility. Health-economics models demonstrate cost-effectiveness versus no screening; USPSTF 2021 included stool-based tests and CMS covers Cologuard for Medicare beneficiaries every 3 years.
Manufacturing and lab operations
High-throughput sample processing at Exact Sciences handles over 1 million clinical samples annually (2024), delivering reliable 24–72 hour turnaround for most workflows. Quality systems keep operations CLIA- and CAP-compliant across their clinical labs. Automation and robotics have improved yield and reduced analytical errors by roughly 30% while boosting throughput above 10,000 samples per day. Capacity planning and flexible shifts enable scaling for seasonality and demand spikes.
Commercial sales and medical education
Multi-channel field teams engage providers and payers to drive adoption and reimbursement for screening products; medical science liaisons disseminate peer-reviewed data to clinicians and institutions to support guideline inclusion. Patient outreach programs increase screening completion rates while digital campaigns bolster adherence and timely re-screening.
- Field teams: provider & payer engagement
- MSLs: peer-reviewed data dissemination
- Patient outreach: screening completion
- Digital campaigns: adherence & re-screening
Data integration and informatics
Data integration and informatics enable interoperability with EHRs and e-ordering to simplify clinician workflows, leveraging the fact that 96% of US hospitals use certified EHRs (ONC). Centralized data warehouses consolidate clinical and operational metrics, while AI risk-stratification models improve test performance and secure analytics support payer and provider reporting.
- Interoperability: EHR integration (96% hospital EHR adoption)
- Consolidation: centralized data warehouses for metrics
- AI: enhanced risk stratification and test accuracy
- Reporting: secure analytics for payers/providers
Assay R&D boosts screening: 92.3% sens / 89.8% spec, 24–72h TAT
Assay R&D (Cologuard, blood/tissue) drives pipeline; DeeP-C Cologuard sensitivity 92.3% / specificity 89.8%, CMS covers every 3 years. Labs processed >1,000,000 samples in 2024 with 24–72h TAT, CLIA/CAP; automation cut errors ~30% and supports >10,000/day. Field teams, MSLs, EHR integration (96% hospital EHR adoption) and AI enable adoption and payer reporting.
| Metric | 2024 |
|---|---|
| Samples processed | >1,000,000 |
| Cologuard Sens/Spec | 92.3% / 89.8% |
| TAT | 24–72h |
| Throughput | >10,000/day |
| EHR adoption | 96% |
Preview Before You Purchase
Business Model Canvas
The Business Model Canvas for Exact Sciences shown here is the actual deliverable, not a mockup. When you purchase, you’ll receive this same complete document—fully formatted and editable. Files are provided ready to use for analysis, presentation, and sharing.
Investor-ready Business Model Canvas for a leading molecular diagnostics innovator
Unlock the full strategic blueprint behind Exact Sciences's Business Model Canvas. This in-depth map shows how the company creates value through innovative diagnostics, commercial partnerships, and diversified revenue streams while spotlighting competitive advantages and key risks. Purchase the complete, editable canvas for section-by-section insights ideal for investor decks, strategic planning, or benchmarking.
Partnerships
Payer and insurer alliances
Reimbursement agreements with Medicare (coverage since 2014) and payers covering over 90% of commercial lives ensure broad access to Cologuard and precision oncology tests. These partnerships lower patient out-of-pocket costs and accelerate adoption. Joint value dossiers and outcomes data drive favorable policies, while multiyear payer contracts improve revenue visibility.
Healthcare provider networks
Primary care (about 70% of screening referrals), GI specialists and oncology clinics serve as critical referral sources for Exact Sciences tests. Co-developed clinical pathways with health systems and networks embed tests into standard care across hundreds of organizations. Targeted clinician education and streamlined sample logistics reduce ordering friction and speed result delivery. Key opinion leaders accelerate evidence adoption and drive guideline inclusion.
Laboratory and logistics partners
Exact Sciences leverages CLIA-certified labs and high-throughput partners to scale testing quality within the ~100 billion USD US clinical lab market in 2024, while cold-chain and courier networks ensure reliable sample transport. Integrated LIMS and interoperability trim turnaround times, and capacity partners enable spikes in demand and new-test launches.
Research institutions and biopharma
Research centers supply cohorts, biobanks and trial sites to validate biomarkers, enabling Exact Sciences to link diagnostics to targeted therapies with biopharma partners; in 2024 Exact Sciences reported roughly $3.3B revenue, supporting expanded RWE programs that strengthened clinical utility claims and yielded co-publications boosting credibility.
- Academic cohorts and biobanks
- Biopharma companion diagnostics
- RWE studies (2024 scale-up)
- Co-publications increase adoption
Regulatory and advocacy collaborations
Engagement with FDA, CMS, and guideline bodies aligns test development and reimbursement, leveraging Medicare coverage of Cologuard for beneficiaries 50–85 every 3 years. Patient advocacy groups such as American Cancer Society amplify awareness and adherence. Public health and policy partnerships drive population screening and support USPSTF screening guidance for ages 45–75.
- Medicare coverage: beneficiaries 50–85 every 3 years
- USPSTF: screening 45–75
- Advocacy: ACS partnership
Medicare coverage, payer reach >90%, primary care referrals ~70%, 2024 revenue $3.3B
Reimbursement deals (Medicare coverage since 2014; payers cover >90% commercial lives) and multiyear contracts drive access and revenue visibility. Referral partnerships (primary care ~70% of screening referrals) and health systems embed Cologuard into care. CLIA labs, couriers and biopharma RWE alliances scaled capacity—2024 revenue ~$3.3B.
| Metric | 2024 |
|---|---|
| Revenue | $3.3B |
| US lab market | $100B |
| Commercial lives covered | >90% |
| Primary care referrals | ~70% |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas tailored to Exact Sciences that maps its nine core blocks—value propositions, customer segments, channels, revenue streams, key resources, activities, partners, cost structure, and customer relationships—against real-world diagnostics and molecular screening operations. Includes competitive advantages, SWOT-linked insights, and polished narratives ideal for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Exact Sciences that condenses its diagnostic and screening strategy into a one-page snapshot, saving hours of structuring while enabling quick comparisons, team collaboration, and fast deliverables for boardrooms or analysts.
Activities
Assay R&D and biomarker discovery
Continuous innovation across multi-target stool DNA (Cologuard), blood-based, and tissue assays drives Exact Sciences pipeline expansion; Cologuard showed 92% sensitivity and 87% specificity for colorectal cancer in pivotal validation.
Rigorous analytical validation programs confirm sensitivity and specificity benchmarks for each assay.
Advanced bioinformatics refines molecular signatures from large clinical datasets, while a growing IP portfolio secures competitive advantage.
Clinical trials and evidence generation
Prospective DeeP-C trial showed Cologuard sensitivity for colorectal cancer 92.3% and specificity 89.8%. Retrospective and real-world studies corroborate clinical validity and utility. Health-economics models demonstrate cost-effectiveness versus no screening; USPSTF 2021 included stool-based tests and CMS covers Cologuard for Medicare beneficiaries every 3 years.
Manufacturing and lab operations
High-throughput sample processing at Exact Sciences handles over 1 million clinical samples annually (2024), delivering reliable 24–72 hour turnaround for most workflows. Quality systems keep operations CLIA- and CAP-compliant across their clinical labs. Automation and robotics have improved yield and reduced analytical errors by roughly 30% while boosting throughput above 10,000 samples per day. Capacity planning and flexible shifts enable scaling for seasonality and demand spikes.
Commercial sales and medical education
Multi-channel field teams engage providers and payers to drive adoption and reimbursement for screening products; medical science liaisons disseminate peer-reviewed data to clinicians and institutions to support guideline inclusion. Patient outreach programs increase screening completion rates while digital campaigns bolster adherence and timely re-screening.
- Field teams: provider & payer engagement
- MSLs: peer-reviewed data dissemination
- Patient outreach: screening completion
- Digital campaigns: adherence & re-screening
Data integration and informatics
Data integration and informatics enable interoperability with EHRs and e-ordering to simplify clinician workflows, leveraging the fact that 96% of US hospitals use certified EHRs (ONC). Centralized data warehouses consolidate clinical and operational metrics, while AI risk-stratification models improve test performance and secure analytics support payer and provider reporting.
- Interoperability: EHR integration (96% hospital EHR adoption)
- Consolidation: centralized data warehouses for metrics
- AI: enhanced risk stratification and test accuracy
- Reporting: secure analytics for payers/providers
Assay R&D boosts screening: 92.3% sens / 89.8% spec, 24–72h TAT
Assay R&D (Cologuard, blood/tissue) drives pipeline; DeeP-C Cologuard sensitivity 92.3% / specificity 89.8%, CMS covers every 3 years. Labs processed >1,000,000 samples in 2024 with 24–72h TAT, CLIA/CAP; automation cut errors ~30% and supports >10,000/day. Field teams, MSLs, EHR integration (96% hospital EHR adoption) and AI enable adoption and payer reporting.
| Metric | 2024 |
|---|---|
| Samples processed | >1,000,000 |
| Cologuard Sens/Spec | 92.3% / 89.8% |
| TAT | 24–72h |
| Throughput | >10,000/day |
| EHR adoption | 96% |
Preview Before You Purchase
Business Model Canvas
The Business Model Canvas for Exact Sciences shown here is the actual deliverable, not a mockup. When you purchase, you’ll receive this same complete document—fully formatted and editable. Files are provided ready to use for analysis, presentation, and sharing.
Original: $10.00
-65%$10.00
$3.50Description
Investor-ready Business Model Canvas for a leading molecular diagnostics innovator
Unlock the full strategic blueprint behind Exact Sciences's Business Model Canvas. This in-depth map shows how the company creates value through innovative diagnostics, commercial partnerships, and diversified revenue streams while spotlighting competitive advantages and key risks. Purchase the complete, editable canvas for section-by-section insights ideal for investor decks, strategic planning, or benchmarking.
Partnerships
Payer and insurer alliances
Reimbursement agreements with Medicare (coverage since 2014) and payers covering over 90% of commercial lives ensure broad access to Cologuard and precision oncology tests. These partnerships lower patient out-of-pocket costs and accelerate adoption. Joint value dossiers and outcomes data drive favorable policies, while multiyear payer contracts improve revenue visibility.
Healthcare provider networks
Primary care (about 70% of screening referrals), GI specialists and oncology clinics serve as critical referral sources for Exact Sciences tests. Co-developed clinical pathways with health systems and networks embed tests into standard care across hundreds of organizations. Targeted clinician education and streamlined sample logistics reduce ordering friction and speed result delivery. Key opinion leaders accelerate evidence adoption and drive guideline inclusion.
Laboratory and logistics partners
Exact Sciences leverages CLIA-certified labs and high-throughput partners to scale testing quality within the ~100 billion USD US clinical lab market in 2024, while cold-chain and courier networks ensure reliable sample transport. Integrated LIMS and interoperability trim turnaround times, and capacity partners enable spikes in demand and new-test launches.
Research institutions and biopharma
Research centers supply cohorts, biobanks and trial sites to validate biomarkers, enabling Exact Sciences to link diagnostics to targeted therapies with biopharma partners; in 2024 Exact Sciences reported roughly $3.3B revenue, supporting expanded RWE programs that strengthened clinical utility claims and yielded co-publications boosting credibility.
- Academic cohorts and biobanks
- Biopharma companion diagnostics
- RWE studies (2024 scale-up)
- Co-publications increase adoption
Regulatory and advocacy collaborations
Engagement with FDA, CMS, and guideline bodies aligns test development and reimbursement, leveraging Medicare coverage of Cologuard for beneficiaries 50–85 every 3 years. Patient advocacy groups such as American Cancer Society amplify awareness and adherence. Public health and policy partnerships drive population screening and support USPSTF screening guidance for ages 45–75.
- Medicare coverage: beneficiaries 50–85 every 3 years
- USPSTF: screening 45–75
- Advocacy: ACS partnership
Medicare coverage, payer reach >90%, primary care referrals ~70%, 2024 revenue $3.3B
Reimbursement deals (Medicare coverage since 2014; payers cover >90% commercial lives) and multiyear contracts drive access and revenue visibility. Referral partnerships (primary care ~70% of screening referrals) and health systems embed Cologuard into care. CLIA labs, couriers and biopharma RWE alliances scaled capacity—2024 revenue ~$3.3B.
| Metric | 2024 |
|---|---|
| Revenue | $3.3B |
| US lab market | $100B |
| Commercial lives covered | >90% |
| Primary care referrals | ~70% |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas tailored to Exact Sciences that maps its nine core blocks—value propositions, customer segments, channels, revenue streams, key resources, activities, partners, cost structure, and customer relationships—against real-world diagnostics and molecular screening operations. Includes competitive advantages, SWOT-linked insights, and polished narratives ideal for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Exact Sciences that condenses its diagnostic and screening strategy into a one-page snapshot, saving hours of structuring while enabling quick comparisons, team collaboration, and fast deliverables for boardrooms or analysts.
Activities
Assay R&D and biomarker discovery
Continuous innovation across multi-target stool DNA (Cologuard), blood-based, and tissue assays drives Exact Sciences pipeline expansion; Cologuard showed 92% sensitivity and 87% specificity for colorectal cancer in pivotal validation.
Rigorous analytical validation programs confirm sensitivity and specificity benchmarks for each assay.
Advanced bioinformatics refines molecular signatures from large clinical datasets, while a growing IP portfolio secures competitive advantage.
Clinical trials and evidence generation
Prospective DeeP-C trial showed Cologuard sensitivity for colorectal cancer 92.3% and specificity 89.8%. Retrospective and real-world studies corroborate clinical validity and utility. Health-economics models demonstrate cost-effectiveness versus no screening; USPSTF 2021 included stool-based tests and CMS covers Cologuard for Medicare beneficiaries every 3 years.
Manufacturing and lab operations
High-throughput sample processing at Exact Sciences handles over 1 million clinical samples annually (2024), delivering reliable 24–72 hour turnaround for most workflows. Quality systems keep operations CLIA- and CAP-compliant across their clinical labs. Automation and robotics have improved yield and reduced analytical errors by roughly 30% while boosting throughput above 10,000 samples per day. Capacity planning and flexible shifts enable scaling for seasonality and demand spikes.
Commercial sales and medical education
Multi-channel field teams engage providers and payers to drive adoption and reimbursement for screening products; medical science liaisons disseminate peer-reviewed data to clinicians and institutions to support guideline inclusion. Patient outreach programs increase screening completion rates while digital campaigns bolster adherence and timely re-screening.
- Field teams: provider & payer engagement
- MSLs: peer-reviewed data dissemination
- Patient outreach: screening completion
- Digital campaigns: adherence & re-screening
Data integration and informatics
Data integration and informatics enable interoperability with EHRs and e-ordering to simplify clinician workflows, leveraging the fact that 96% of US hospitals use certified EHRs (ONC). Centralized data warehouses consolidate clinical and operational metrics, while AI risk-stratification models improve test performance and secure analytics support payer and provider reporting.
- Interoperability: EHR integration (96% hospital EHR adoption)
- Consolidation: centralized data warehouses for metrics
- AI: enhanced risk stratification and test accuracy
- Reporting: secure analytics for payers/providers
Assay R&D boosts screening: 92.3% sens / 89.8% spec, 24–72h TAT
Assay R&D (Cologuard, blood/tissue) drives pipeline; DeeP-C Cologuard sensitivity 92.3% / specificity 89.8%, CMS covers every 3 years. Labs processed >1,000,000 samples in 2024 with 24–72h TAT, CLIA/CAP; automation cut errors ~30% and supports >10,000/day. Field teams, MSLs, EHR integration (96% hospital EHR adoption) and AI enable adoption and payer reporting.
| Metric | 2024 |
|---|---|
| Samples processed | >1,000,000 |
| Cologuard Sens/Spec | 92.3% / 89.8% |
| TAT | 24–72h |
| Throughput | >10,000/day |
| EHR adoption | 96% |
Preview Before You Purchase
Business Model Canvas
The Business Model Canvas for Exact Sciences shown here is the actual deliverable, not a mockup. When you purchase, you’ll receive this same complete document—fully formatted and editable. Files are provided ready to use for analysis, presentation, and sharing.
